ES541450A0 - Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas. - Google Patents

Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.

Info

Publication number
ES541450A0
ES541450A0 ES541450A ES541450A ES541450A0 ES 541450 A0 ES541450 A0 ES 541450A0 ES 541450 A ES541450 A ES 541450A ES 541450 A ES541450 A ES 541450A ES 541450 A0 ES541450 A0 ES 541450A0
Authority
ES
Spain
Prior art keywords
heteroazolidindionas
spire
procedure
preparation
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES541450A
Other languages
English (en)
Other versions
ES8606295A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES541450A0 publication Critical patent/ES541450A0/es
Publication of ES8606295A1 publication Critical patent/ES8606295A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES541450A 1984-03-23 1985-03-21 Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas. Expired ES8606295A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59301284A 1984-03-23 1984-03-23

Publications (2)

Publication Number Publication Date
ES541450A0 true ES541450A0 (es) 1986-04-16
ES8606295A1 ES8606295A1 (es) 1986-04-16

Family

ID=24372993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES541450A Expired ES8606295A1 (es) 1984-03-23 1985-03-21 Un procedimiento para la preparacion de nuevas espiro-3-heteroazolidindionas.

Country Status (15)

Country Link
EP (1) EP0159143B1 (es)
JP (1) JPS60209572A (es)
KR (1) KR850006188A (es)
AU (1) AU563668B2 (es)
CA (1) CA1244443A (es)
DE (1) DE3561198D1 (es)
DK (1) DK131885A (es)
ES (1) ES8606295A1 (es)
FI (1) FI851170A7 (es)
GR (1) GR850704B (es)
HU (1) HU195783B (es)
IL (1) IL74667A (es)
PH (1) PH23921A (es)
PL (1) PL145198B1 (es)
PT (1) PT80145B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
ATE516803T1 (de) 2003-03-14 2011-08-15 Merck Sharp & Dohme Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
ATE518852T1 (de) * 2004-09-13 2011-08-15 Merck Sharp & Dohme Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
CN111732545B (zh) * 2020-06-08 2023-03-10 华侨大学 一种2,3-二氢螺[咪唑-4,1′-茚]类化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
ES8400116A1 (es) * 1981-10-13 1983-10-16 Pfizer "un procedimiento por analogia para la preparacion de derivados de espiro-oxindol-oxazolidindiona".
ZA832679B (en) * 1982-05-07 1983-12-28 Ici Plc Indoline derivatives
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications

Also Published As

Publication number Publication date
AU563668B2 (en) 1987-07-16
JPS60209572A (ja) 1985-10-22
PT80145A (en) 1985-04-01
DK131885D0 (da) 1985-03-22
FI851170L (fi) 1985-09-24
DE3561198D1 (en) 1988-01-28
IL74667A0 (en) 1985-06-30
PL145198B1 (en) 1988-08-31
CA1244443A (en) 1988-11-08
EP0159143B1 (en) 1987-12-16
KR850006188A (ko) 1985-10-02
HU195783B (en) 1988-07-28
PL252487A1 (en) 1985-10-08
FI851170A0 (fi) 1985-03-22
GR850704B (es) 1985-07-19
PT80145B (en) 1987-03-23
EP0159143A1 (en) 1985-10-23
DK131885A (da) 1985-09-24
FI851170A7 (fi) 1985-09-24
HUT37603A (en) 1986-01-23
PH23921A (en) 1990-01-23
ES8606295A1 (es) 1986-04-16
IL74667A (en) 1988-12-30
AU4025185A (en) 1985-09-26

Similar Documents

Publication Publication Date Title
ES545464A0 (es) Un procedimiento para la preparacion de tetrahidroftalimidas.
ES540705A0 (es) Un procedimiento para la preparacion de 17b-carbamoil-n-monosustituido -o 17b-acil-4-aza-5-alfa-androstien-3-onas.
ES544644A0 (es) Un procedimiento para la preparacion de derivados de carboxamidoadenosina.
ES555834A0 (es) Un procedimiento para la preparacion de nuevas piranopiridinas.
ES551249A0 (es) Un procedimiento para la preparacion de peptidilaminodioles.
ES556738A0 (es) Un procedimiento para la preparacion de nuevos piridazinaminas.
ES541200A0 (es) Un procedimiento para la preparacion de un derivado de dibenzoilmetano.
ES533753A0 (es) Un procedimiento para la preparacion de nuevas fenoxialquil-1-2-4-triazolonas.
ES546236A0 (es) Un procedimiento para la preparacion de derivados de bencimidasol.
ES540609A0 (es) Un procedimiento para la preparacion de pirazolo piridinas.
ES554983A0 (es) Un procedimiento para la preparacion de silileteres.
ES540610A0 (es) Un procedimiento para la preparacion de pirazolopiridinas.
ES546872A0 (es) Un procedimiento para la preparacion de aminoalcoxibenzopiranonas.
ES544521A0 (es) Un procedimiento para la preparacion de triazolobenzodiazefinas.
ES557076A0 (es) Un procedimiento para la preparacion de nuevas benzamidas sustituidas.
ES541781A0 (es) Un procedimiento para la preparacion de nuevos benzotiopenos.
ES550504A0 (es) Un procedimiento para la preparacion de derivados de podofilotoxina.
ES547805A0 (es) Un procedimiento para la preparacion de nuevos derivados de guanina.
ES555369A0 (es) Un procedimiento para la preparacion de un polialquenoilisocianato.
ES540200A0 (es) Un procedimiento para la preparacion de acidos 7-amino-3-me-til sustituido-3-defem-4-carboxilicos
ES539543A0 (es) Un procedimiento para la preparacion de nuevos compuestos de oxadiazinona.
ES547205A0 (es) Un procedimiento para la preparacion de nuevas quinazolindionas.
ES555723A0 (es) Un procedimiento para la preparacion de tetrahidroimidazoquinazolinonas.
ES516184A0 (es) "un metodo para la preparacion de 3-fenil-1-indanaminas".
ES542882A0 (es) Un procedimiento para la preparacion de nuevas sulfonilureas.